تداخلهای دارویی
Daunorubicin + Trastuzumab deruxtecan
شدت: شدید
Daunorubicin and Trastuzumab deruxtecan: major interaction.
آخرین بهروزرسانی
ویژه کادر درمان — فقط جهت مرجع. این صفحه خلاصهای کوتاه است، توصیه پزشکی نیست و جایگزین بروشور رسمی یا قضاوت بالینی نمیشود. پیش از تجویز یا تحویل دارو همیشه بررسی کنید.
محتوای بالینی این صفحه فقط به زبان انگلیسی موجود است.
خلاصه
Anthracyclines and HER2-directed antibodies both carry cardiotoxicity risk, and giving them together or in close sequence increases the risk of cardiomyopathy and reduced ejection fraction. Trastuzumab deruxtecan also causes interstitial lung disease and myelosuppression.
معنای این تداخل به زبان ساده
Daunorubicin and Trastuzumab deruxtecan can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Daunorubicin belongs to Oncology; Trastuzumab deruxtecan belongs to Oncology.
چرا رخ میدهد
Additive cardiotoxicity from anthracycline myocardial injury and HER2 pathway inhibition in cardiomyocytes.
اقدام لازم
Avoid concurrent use and keep the interval between anthracycline and HER2-directed therapy as long as possible. Assess left ventricular ejection fraction before and regularly during treatment.
از داروساز چه بپرسید
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
ویژه اعضای Pro+
باز کردن کل صفحه
یک حساب بسازید و دوره آزمایشی Pro+ را شروع کنید تا توصیههای کامل مدیریت Daunorubicin و Trastuzumab deruxtecan، یادداشتهای تکمیلی، جزئیات شواهد و بررسیکننده تداخل برای کل نسخه را باز کنید.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Pro+ را ۱۴ روز رایگان در وب امتحان کنید. بدون نیاز به کارت.
تداخلات دیگر Daunorubicin
تداخلات دیگر Trastuzumab deruxtecan
پرسشهای متداول
Can I take Daunorubicin with Trastuzumab deruxtecan?
MediHelp rates the interaction as major. Daunorubicin and Trastuzumab deruxtecan can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Anthracyclines and HER2-directed antibodies both carry cardiotoxicity risk, and giving them together or in close sequence increases the risk of cardiomyopathy and reduced ejection fraction. Trastuzumab deruxtecan also causes interstitial lung disease and myelosuppression.
How serious is the interaction between Daunorubicin and Trastuzumab deruxtecan?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid concurrent use and keep the interval between anthracycline and HER2-directed therapy as long as possible. Assess left ventricular ejection fraction before and regularly during treatment.
What other medicines interact with Daunorubicin?
MediHelp also lists interactions of Daunorubicin with, for example, Adenovirus types 4 and 7 live, Belatacept, Cyclosporine. The full list is on the Daunorubicin page.
تکنگاری کامل، دوزاژ و بررسی تداخل دارویی در برنامه MediHelp
مرجع کامل را باز کنید، تداخل چند دارو را بررسی کنید و از ابزارهای دوز در برنامه MediHelp استفاده کنید.